Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Jardiance (empagliflozin) and Ozempic (semaglutide) are both medications used to treat Type 2 diabetes and help lower the risk of heart problems in adults with this condition. However, they belong to different medication classes and have distinct characteristics. Jardiance is a sodium-glucose cotransporter 2 (SGLT2) inhibitor taken orally once a day, while Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist injected subcutaneously (under the skin) once a week. Both are available only as brand name medications. Common side effects of Jardiance include urinary tract infections and yeast infections, while Ozempic often causes nausea, vomiting, and diarrhea. Jardiance can lead to dehydration and low blood pressure, whereas Ozempic carries a risk of thyroid cancer and pancreatitis. Both medications can cause low blood sugar when used with other diabetes treatments, but they have different mechanisms and dosing schedules, which may influence preferences for one over the other.
Ozempic (semaglutide) is a GLP-1 agonist used with diet and exercise to help adults manage Type 2 diabetes. It can also lower the risk of heart attack, stroke, and heart-related death in some people with Type 2 diabetes. It comes as a once-weekly injection under the skin and as a tablet taken by mouth once a day. The injection is also approved to help slow worsening kidney problems in people with Type 2 diabetes and chronic kidney disease (CKD). Common side effects include nausea, vomiting, and diarrhea.
Indications of Jardiance vs. Ozempic
Indications for
•Type 2 diabetes (in addition to diet and exercise) in people age 10 years and older
•Lowering the risk of death due to heart problems in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization and death due to heart problems in adults with heart failure
•Lowering the risk of worsening kidney problems, hospitalization, and death due to heart problems in adults with chronic kidney disease (CKD)